PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

• Published in: The Prostate Vol. 80; no. 1; pp. 99 - 108
• Main Authors: Petrylak, Daniel P., Vogelzang, Nicholas J., Chatta, Kamal, Fleming, Mark T., Smith, David C., Appleman, Leonard J., Hussain, Arif, Modiano, Manuel, Singh, Parminder, Tagawa, Scott T., Gore, Ira, McClay, Edward F., Mega, Anthony E., Sartor, A. Oliver, Somer, Bradley, Wadlow, Raymond, Shore, Neal D., Olson, William C., Stambler, Nancy, DiPippo, Vincent A., Israel, Robert J.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.01.2020
• Subjects: Aged; Aged, 80 and over; Androstenes - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; antibody‐drug conjugate; Antigens; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antitumor activity; Biomarkers, Tumor - blood; Castration; Chemotherapy; Constipation; Cytotoxicity; Dehydration; Drug Resistance, Neoplasm; Humans; Hyponatremia; Immunoglobulin G; Immunotoxins - adverse effects; Immunotoxins - therapeutic use; Male; mCRPC; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Neuropathy; Neutropenia; Oncology; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - analogs & derivatives; Prostate cancer; prostate‐specific membrane antigen; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - diagnostic imaging; Prostatic Neoplasms, Castration-Resistant - drug therapy; Sepsis; Survival Rate; Terminology; Treatment Outcome; Tumor cells; mCRPC; antibody-drug conjugate; prostate-specific membrane antigen

Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody‐drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti‐PSMA monoclonal antibody conjugated to monomethy...